search
Back to results

Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease

Primary Purpose

Peripheral Vascular Disease

Status
Unknown status
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Liprostin [liposomal Prostaglandin E1]
Sponsored by
Endovasc
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Vascular Disease focused on measuring Angioplasty & PGE1 Treatment of Peripheral Vascular Disease

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female subjects, 18 years and older Diagnosis of Peripheral Arterial Occlusive Disease [PAOD] Subject is a candidate for immediate angioplasty of the lower limb Subject must complete 2 treadmill tests at Screen in which walking distance is limited by PAOD and not due to angina or fatigue Exclusion Criteria: Lower limb peripheral re-vascularization procedures in past 3 months History of myocardial infarction in the past 6 months Malignant disease, uncontrolled hypertension or Class III heart failure Aortic occlusion, thrombosed popliteal aneurysm, severe hemorrhagic disorder, or a long iliac occlusion

Sites / Locations

  • Memorial Hermann HospitalRecruiting

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
February 4, 2003
Last Updated
March 6, 2007
Sponsor
Endovasc
search

1. Study Identification

Unique Protocol Identification Number
NCT00053716
Brief Title
Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease
Official Title
Phase II, Single Center, Non-Controlled, Open-Label Study of Liposomal Prostaglandin E1 (Liprostin) as Adjunct Therapy With Lower Limb Angioplasty in Patients With Ischemic and Non-Ischemic Peripheral Arterial Occlusive Disease
Study Type
Interventional

2. Study Status

Record Verification Date
March 2004
Overall Recruitment Status
Unknown status
Study Start Date
February 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
August 2003 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Endovasc

4. Oversight

5. Study Description

Brief Summary
This is the first clinical research trial in which intravenous Prostaglandin E1 (PGE1 is a vasoactive hormone) will be used as supportive treatment along with the angioplasty procedure to treat or open up a blocked artery within one lower limb or the most affected of two limbs in subjects with Peripheral Arterial Occlusive Disease.
Detailed Description
PAOD results in a decrease in arterial blood flow to the lower limb and feet with symptoms that can include, pain at rest, a numbing sensation in limb or feet, limited ability to walk before pain occurs. PAOD can occur along with diabetic ulcers. Proposed treatment will be given at a medical center with an overnight hospital stay. Treatment includes angioplasty to open up one or two occluded arteries in a lower limb plus a drug (Liprostin) a special formulation of liposomal Prostaglandin E1,or PGE1, a natural occuring vasoactive hormone). Drug treatment is given twice to each artery to be treated, just before and after angioplasty. When angioplasty procedure is completed, a 12 hour intravenous infusion of Liprostin is given to complete the treatment procedure. A total of 12 PAOD subjects will be enrolled in a single center: Memorial Hermann Hospital, Houston, TX. Study will begin in February, 2003 with the last (12th) subject to be enrolled, likely by August, 20

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Vascular Disease
Keywords
Angioplasty & PGE1 Treatment of Peripheral Vascular Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
12 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Liprostin [liposomal Prostaglandin E1]

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects, 18 years and older Diagnosis of Peripheral Arterial Occlusive Disease [PAOD] Subject is a candidate for immediate angioplasty of the lower limb Subject must complete 2 treadmill tests at Screen in which walking distance is limited by PAOD and not due to angina or fatigue Exclusion Criteria: Lower limb peripheral re-vascularization procedures in past 3 months History of myocardial infarction in the past 6 months Malignant disease, uncontrolled hypertension or Class III heart failure Aortic occlusion, thrombosed popliteal aneurysm, severe hemorrhagic disorder, or a long iliac occlusion
Facility Information:
Facility Name
Memorial Hermann Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Catey Carter, RN
Phone
713-500-6550
Email
catharine.v.carter@uth.tmc.edu
First Name & Middle Initial & Last Name & Degree
Carol J Underwood, RN
Phone
713-500-6563
Email
carol.j.underwood@uth.tmc.edu
First Name & Middle Initial & Last Name & Degree
Richard W. Smalling, M.D., Ph.D

12. IPD Sharing Statement

Learn more about this trial

Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease

We'll reach out to this number within 24 hrs